Literature DB >> 17641409

Beta 3-adrenoceptors in the cardiovascular system.

Chantal Gauthier1, Camille Sèze-Goismier, Bertrand Rozec.   

Abstract

The sympathetic system is central in the understanding of numerous physiological and physiopathological phenomena. During the last decade, the characterization of a new beta-adrenoceptor subtype, beta(3), in addition to beta(1) and beta(2)-adrenoceptor in the cardiovascular system has changed the view of the roles of the sympathetic system. In heart, beta(3)-adrenoceptor stimulation produce an opposite effect to that induced by beta(1) and beta(2)-adrenoceptors suggesting that in normal heart, the negative inotropic effect induced by the beta(3)-adrenergic stimulation might play a role of a "safety-valve" during intense adrenergic stimulation. In vessels, all beta-adrenoceptors subtypes, beta(1), beta(2) and beta(3), mediate a vasodilation. As beta(3)-adrenoceptors are activated at higher concentrations of catecholamines than beta(1) and beta(2)-adrenoceptors, they could play the roll of a receptor reserve. beta(3)-adrenoceptors are overexpressed in heart failure and hypertension and could constitute a new therapeutic target. In addition, the efficiency of some beta-blockers such as nebivolol could result from an action on beta(3)-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641409

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  8 in total

1.  Role of β-blocker therapy in pediatric heart failure.

Authors:  Akash R Patel; Robert E Shaddy
Journal:  Ped Health       Date:  2010

2.  Calcium response of KCl-excited populations of ventricular myocytes from the European sea bass (Dicentrarchus labrax): a promising approach to integrate cell-to-cell heterogeneity in studying the cellular basis of fish cardiac performance.

Authors:  Hélène Ollivier; James Marchant; Nicolas Le Bayon; Arianna Servili; Guy Claireaux
Journal:  J Comp Physiol B       Date:  2015-07-24       Impact factor: 2.200

3.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor.

Authors:  An L Moens; Jordan S Leyton-Mange; Xiaolin Niu; Ronghua Yang; Oscar Cingolani; Elisabeth K Arkenbout; Hunter C Champion; Djahida Bedja; Kathleen L Gabrielson; Juan Chen; Yong Xia; Ashley B Hale; Keith M Channon; Marc K Halushka; Norman Barker; Floris L Wuyts; Pawel M Kaminski; Michael S Wolin; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

4.  PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.

Authors:  Dong I Lee; Susan Vahebi; Carlo Gabriele Tocchetti; Lili A Barouch; R John Solaro; Eiki Takimoto; David A Kass
Journal:  Basic Res Cardiol       Date:  2010-01-27       Impact factor: 17.165

5.  β(3)-Adrenoceptor Antagonist SR59230A Attenuates the Imbalance of Systemic and Myocardial Oxygen Transport Induced by Dopamine in Newborn Lambs.

Authors:  Richdeep S Gill; Po-Yin Cheung; Xiaoyang Yu; Mohammed Al Aklabi; Jeevan Nagendran; Luis G Quinonez; Ying Qian Li; John Miller; David B Ross; Ivan M Rebeyka; Jia Li
Journal:  Clin Med Insights Cardiol       Date:  2012-02-16

Review 6.  Role of peroxynitrite in the redox regulation of cell signal transduction pathways.

Authors:  Lucas Liaudet; Giuseppe Vassalli; Pal Pacher
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

7.  Relationship between the autoantibody and expression of β3-adrenoceptor in lung and heart.

Authors:  Guobin Miao; Zhe Chen; Xiangyang Fang; Miaobing Liu; Gang Hao; Huiling An; Zhiyong Zhang; Lingqiao Lu; Jian Zhang; Lin Zhang
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

8.  A modified approach to induce predictable congestive heart failure by volume overload in rats.

Authors:  Sascha Treskatsch; Aarne Feldheiser; Adrian T Rosin; Marco Sifringer; Helmut Habazettl; Shaaban A Mousa; Mehdi Shakibaei; Michael Schäfer; Claudia D Spies
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.